This FAQ page has been developed to help healthcare professionals (HCPs) understand the new regulatory position on isotretinoin prescribing. Before reading these FAQs, you should read the Commission on Human Medicines’ (CHM) Isotretinoin Implementation Advisory Expert Working Group (IIAEWG) report.

For queries and feedback relating to the principles of these regulatory changes, please email the MHRA directly (info@mhra.gov.uk). For queries and feedback relating to the documents and tools produced by the BAD to support members in implementing these regulatory changes please email the BAD’s Clinical Standards Unit (clinicalstandards@bad.org.uk).